UNITY Biotechnology Completes Enrollment in Phase 1b Study of UBX0101
Unity Biotechnology, Inc. (UBX)
Last unity biotechnology, inc. earnings: 3/11 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
SAN FRANCISCO, March 31, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced updates related to UBX0101. In February 2020, UNITY announced that it had dosed the first patients with moderate-to-severe osteoarthritis (OA) of the knee in a Phase 1b study to explore the safety, tolerability and initial efficacy of a single 8.0 mg dose or multiple doses (two 4.0 mg doses separated by one month) of UBX0101, an inhibitor of the p53/MDM2 protein-protein interaction. The study has now completed enrollment of 35 patients. Both 12- and 24-week data are currently expected in the second half of 2020. Also in February 2020, UNITY announced completion of enrollment of a Phase 2 study of UBX0101 in patients with moderate-to-severe OA of the knee. This study, now fully enrolled with 183 patients, is randomized, double-blind, and placebo-contr
Show less
Read more
Impact Snapshot
Event Time:
UBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UBX alerts
High impacting Unity Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
UBX
News
- ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates [Yahoo! Finance]Yahoo! Finance
- All You Need to Know About UNITY Biotechnology (UBX) Rating Upgrade to Buy [Yahoo! Finance]Yahoo! Finance
- EHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress [Yahoo! Finance]Yahoo! Finance
- Unity Biotechnology, Inc. (NASDAQ: UBX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.MarketBeat
- UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates [Yahoo! Finance]Yahoo! Finance
UBX
Earnings
- 5/14/24 - Beat
UBX
Analyst Actions
- 5/15/24 - HC Wainwright
UBX
Sec Filings
- 5/14/24 - Form 10-Q
- 5/14/24 - Form 8-K
- 5/3/24 - Form 4
- UBX's page on the SEC website